Effect of multiple doses of AZD6280 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2) - CYP
Study identifier:D0850C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase I open-labeled, fixed sequence study to determine the effect of multiple doses of AZD6280 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2)
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6280, Midazolam, Caffeine
Sex
Male
Actual Enrollment
24
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Jan 2009
Primary Completion Date: -
Study Completion Date: 01 Mar 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD6280 oral Drug: Midazolam oral Drug: Caffeine oral |
Contacts
Investigators
Principal Investigator
Darren Wilbraham
Guy’s Drug Research Unit Quintiles Ltd
